Neovacs SA of France has appointed Piers Whitehead to lead manage the company’s search for partners for its immunotherapy business. His title is vice president of corporate development
Prior to joining Neovacs, Mr Whitehead was a biotechnology consultant. Before that, he was vice president of business and corporate development at VaxGen Inc of the US. He is a graduate of Oriel College, Oxford in the UK.
Neovacs is a 1993 spin-out of the Pierre et Marie Curie Paris University.
Copyright 2009 Evernow Publishing Ltd